Your browser doesn't support javascript.
Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2.
Ramot, Yuval; Nanova, Krassimira; Faitatziadou, Sofia-Maria; Assab, Dania Abu; Berkun, Yackov; Zlotogorski, Abraham.
  • Ramot Y; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
  • Nanova K; Clalit Health Services, Jerusalem, Israel.
  • Faitatziadou SM; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
  • Assab DA; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
  • Berkun Y; Department of Pediatrics, Hadassah Mount Scopus Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
  • Zlotogorski A; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
J Dtsch Dermatol Ges ; 20(8): 1123-1124, 2022 08.
Article in English | MEDLINE | ID: covidwho-1886653

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pityriasis Rosea / COVID-19 Vaccines / COVID-19 Type of study: Diagnostic study / Observational study Topics: Vaccines Limits: Humans Language: English Journal: J Dtsch Dermatol Ges Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Ddg.14784

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pityriasis Rosea / COVID-19 Vaccines / COVID-19 Type of study: Diagnostic study / Observational study Topics: Vaccines Limits: Humans Language: English Journal: J Dtsch Dermatol Ges Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Ddg.14784